Larry Green, PhDCEO at AblexisSpeaker
Profile
Larry Green is founder and CEO of Ablexis and AlivaMab Biologics. He brings over thirty years of experience in the development and use of transgenic mice for the discovery of human therapeutic antibodies, contributing to the discovery of nine approved antibody drugs to date. He is an inventor on more than 80 issued patents covering antibody technologies and therapeutic product candidates, including the XenoMouse® technology, in use today at Amgen after the acquisition of Abgenix in 2006. He founded Ablexis in 2009, where he led the design and creation of the AlivaMab® Mouse, which has now grown into a suite of nine (and counting) different transgenic mouse strains optimized for antibody drug discovery and development. Larry received his Ph.D. from the University of Wisconsin-Madison.
Agenda Sessions
Celebrating Diversity: AlivaMab® Discovery and Engineering Platforms for Novel Biologic Therapeutics
, 12:15pmView Session